Work

718TiP KEYNOTE-676 cohort B: Randomized comparator-controlled cohort to evaluate efficacy and safety of pembrolizumab (pembro) plus bacillus Calmette-Guérin (BCG) in patients with high-risk BCG treatment-naive non-muscle invasive bladder cancer (HR NMIBC)

Year: 2021

Type: article

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2021.08.114

Authors: S.F. Shariat, G. Steinberg, A.M. Kamat, N.D. Shore, S. Alanee, H. Nishiyama, K. Nam, J.L. Godwin, E. Kapadia, N. Hahn

Institutions: Medical University of Vienna, NYU Langone Health, The University of Texas MD Anderson Cancer Center, Carolina Urologic Research Center, Detroit Medical Center, Michigan State University, University of Tsukuba, Merck & Co., Inc., Rahway, NJ, USA (United States), Johns Hopkins University, Johns Hopkins Medicine

Language: English

Topic: Bladder and Urothelial Cancer Treatments

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W3202080513

FWCI: 0.237

Cites:

Cited by: 1

Related to: 10